


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	<del>1640</del> 1644
Examiner Name	<del>Unassigned</del> Marianne Dibrino/
Attorney Docket Number	60820.000004

Sheet 1 of 10

**PATENT DOCUMENTS**

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MD	1.	US- 6,245,523	06-12-2001	ALTIERI	_____

**FOREIGN PATENT DOCUMENTS**

*Examiner Initials	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code:	Number - Kind Code (if known)				YES	NO
MD	2.	WO	92/20356	11-26-1992	BOON, T. et al	_____		
MD	3.	WO	94/05304	03-17-1994	BOON-FALLEUR, T., et al	_____		
	4.	WO	97/28816	08-14-1997	JAGER, E., et al	_____		
MD	5.	WO	00/03693	01-27-2000	LEASON, H., et al.	_____		

**NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	6.	VAN DEN EYNDE, B. J. et al., "Tumor antigens recognized by T lymphocytes", Int. J. Clin. Lab. Res., 27:81-86, 1997		
MD	7.	ROSENBERG, S. A., "Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens," J. Natl. Cancer Inst., 22:88: 1635-1644, 1996		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/APTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	<del>1846</del> 1644
Examiner Name	Unassigned/Marianne Dibrino/
Attorney Docket Number	60820.000004

Sheet 2 of 10

**NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	8.	MARCHAND, M. et al., "T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MACE-3 and presented by HLA- A1," Int. J. Cancer, 80: 219-230, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	9.	BROSSART, P. et al., "W. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes," Cancer Res., 58: 732-736, 1998.	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	10.	BROSSART, P. et al., "Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies," Blood, 93:4309-4317, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	11.	VONDERHEIDE, R. et al., "The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes," Immunity, 10:673-679, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	12.	LACASSE, E. C. et al., "The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene, 17:3247-3259, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	13.	ALTIERI, D. C. et al., "Survivin apoptosis: an interloper between cell death and cell proliferation in cancer," Lab Invest, 79:1327-1333, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	14.	AMBROSINI, G. et al., "Induction of apoptosis and inhibition of cell proliferation by survivin, in human melanoma," J. Invest Dermatol., 113:1076-1081, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	15.	GROSSMAN, D. et al., "Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma," J. Invest Dermatol., 113: 1076-1081, 1999.	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	16.	GROSSMAN, D. et al., "Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line," Lab Invest, 79: 1121-1126, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
MD	17.	ANDERSEN, M. H. et al., "An assay for peptide binding to HLA-Cw*0102," Tissue Antigens, 54:185-190, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

/Marianne Dibrino/

DATE CONSIDERED

03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	<del>1646</del> 644
Examiner Name	<del>Unassigned</del> Marianne Dibrino/
Attorney Docket Number	60820.000004

Sheet 3 of 10

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	18.	ANDERSEN, M. H. et al., "Phosphorylated Peptides Can Be Transported by TAP Molecules, Presented by Class I MHC Molecules, and Recognized by Phosphopeptide-Specific CTL. J. Immunol., 163:3812-3188, 1999		
	19.	MCCUTCHEON, M. et al., "A sensitive ELISPOT assay to detect low-frequency human T lymphocytes," J. Immunol. Methods, 210:149-166, 1997		
	20.	PASS, H. A. et al., "Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay," Cancer J. Sci. Am., 4: 316-323, 1998		
	21.	BERKE, Z. et al., "Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules," Leukemia, 14:419-426, 2000		
	22.	FALK, K. et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," Nature, 351:290-296, 1991		
	23.	CORNELISON, T. L., "Human papillomavirus genotype 16 vaccines for cervical cancer prophylaxis and treatment, Curr. Opin. Oncol., 12:466-473, 2000		
	24.	LEE, S. P. et al., "CTL control of EVB in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells," Immunol., 165: 573-582, 2000		
	25.	SWANA, H. S. et al., "Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N. Engl. J. Med., 341: 452-453, 1999		
MD	26.	SALGALLER, M. L. et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/715,417
Filing Date	November 19, 2003
First Named Inventor	Eivind Per Thor STRATEN et al.
Art Unit	<del>1040</del> 1644
Examiner Name	<del>Unassigned</del> Marianne Dibrino/
Attorney Docket Number	60820.000004

Sheet 4 of 10

## NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD ↓	27.	SALGALLER, H. L. et. al., "Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptide," Cancer Res., 56:4749-4757, 1996	—	—
	28.	VALMORI, D. et al., "Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998	—	—
	29.	PARDOLL, D. H., "Cancer vaccines," Nat. Med., 4:525-531, 1998	—	—
	30.	KUGLER, A. et al., "Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids," Nat. Med., 6:332-336, 2000	—	—
	31.	BECKER, J. et al., "Accumulation of identical T cells in melanoma and vitiligo-like leukoderma," J. Invest. Dermatol., 113: 1033-1038, 1999	—	—
	32.	ROHAYEM, J. et al., "Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients," Cancer Res., 2000, Apr., 1:60; (7):1815-7., 60: 1815-1817	—	—
	33.	ADIDA, C. et al., "Prognostic significance of survivin expression in diffuse large B-cell lymphomas," Blood, 96: 1921-1925, 2000	—	—
	34.	ISLAM, A. et al., "High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma," Oncogene, 19:617-623, 2000	—	—
	35.	KAWASAKI, H., "Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer," Cancer Res., 58:5071-5074, 1998	—	—
	36.	SCHMITZ, M. et al., "Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides," Cancer Res., 60:4845-4849, 2000	—	—

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**Application Number**

**10/715,417**

**Filing Date**

**November 19, 2003**

**First Named Inventor**

Eivind Per Thor STRATEN et al.

## Art Unit

~~1048~~ 1644

**Examiner Name**

~~Unassigned~~/Marianne Dibrino/

Sheet

**5**

of

10

Attorney Docket Number

**60820.000004**

## NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	37.	ANDERSEN, M. H. et al., "Identification of a Cytotoxic T Lymphocyte Response to the Apoptosis inhibitor Protein Survivin in Cancer Patients," Cancer Res., 61:869-872, 2001		
	38.	LEE, K. H. et al., "Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination," J. Immunol., 161: 4183-4194, 1998		
	39.	ROSENBERG, S. A. et al., "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," Nat. Med., 4: 321-327, 1998		
	40.	ALTMAN, J. D. et al., "Phenotypic analysis of antigen-specific T lymphocytes," Science, 274: 94-96, 1996		
	41.	SCHRAMA, D. et al., "Oligoclonal I-Cell Receptor Usage Of Melanocyte Differentiation Antigen-reactive I Cells in Stage IV Melanoma Patients," Cancer Res., 61: 493-496, 2001		
	42.	LUXEMBOURG, A. T. et al., "Biomagnetic isolation of antigen-specific CCD8+ T cells usable in immunotherapy," Nat. Biotechnol., 16: 281-285, 1998		
	43.	KIRKIN, A. F. et al., "Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines," Cancer Immunol. Immunother., 41: 71-81, 1995		
MD	44.	SCHEIBENBOGEN, C. et al., "A sensitive ELISPOT assay for detection of CD8+T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients," Clin. Cancer Res., 3: 221-226, 1997		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Application Number

10/715,417

Filing Date

November 19, 2003

First Named Inventor

Eivind Per Thor STRATEN et al.

Art Unit

~~7646~~ 1644

Examiner Name

~~Unassigned~~ Marianne Dibrino/

Sheet

6

of

10

Attorney Docket Number

60820.000004

**NON-PATENT LITERATURE DOCUMENTS**

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	45.	thor STRATEN, P. et al., "In Situ I-Cell Responses against Melanoma Comprise High Numbers of Locally Expanded I-Cell Clonotypes," J. Immunol., 163: 443-447, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	46.	KESSLER, J. H. et al., "Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes In the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis," J. Exp. Med., 193: 73-88, 2001	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	47.	de VRIES, T. 3., Fourkour, A., Wobbes, I., Verkroost, G., Ruiter, D. 3., and van Muijen, C. N. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-I, and tyrosinase in human melanoma cell lines and in human melanocytic lesions," Cancer Res., 57: 3223-3229, 1997	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	48.	JAGER, E. et al., "Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo," Int. J. Cancer, 66: 470-476, 1996	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	49.	CORMIER, J. N. et al., "Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy," J. Immunother., 21: 27-31, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>
V MD	50.	RIKER, A. et al., "Immune selection after antigen-specific immunotherapy of melanoma," Surgery, 126: 112-120, 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	51.	MAEURER, N. J., "Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen," J. Clin. Invest, 98: 1633-1641, 1996	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	52.	GROSSMAN, D. et al., "Inhibition of melanoma tumor growth in vivo by survivin targeting," Proc Natl. Acad. Sci. USA, 98: 635-640, 2001	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	53.	TAMM, I. et al., "IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs," Cancer Res., 58: 5315-5320, 1998	<input checked="" type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED

03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Application Number**

**Filing Date****First Named Inventor**

## Art Unit

**Examiner Name**

Sheet

7

**of**

10

Attorney Docket Number

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. -Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**Application Number**

10/715,417

**Filing Date**

**November 19, 2003**

**First Named Inventor**

Eivind Per Thor STRATEN et al.

## Art Unit

1848 1644

**Examiner Name**

~~Unassigned~~ / Marianne Dibrind /

Sheet

8

of

**10**

Attorney Docket Number

**60820.000004**

## NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD ↓	64.	ALTIERI, D. C. et al., "Validating survivin as a cancer therapeutic target," Nat. Rev. Cancer, 3: 46-54, 2003	—	—
	65.	OLIE, R. A. et al., "A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy," Cancer Res, 60: 2805-2809, 2000	—	—
	66.	ANDERSEN, N. H. et al., "Survivin--a universal tumor antigen," Histol. Histopathol., 17: 669-675, 2002	—	—
	67.	ANDERSEN, N. H. et al., "Spontaneous cytotoxic I-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients," Cancer Res, 61: 5964-5968, 2001	—	—
	68.	CURRIER, J. R. et al., "A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays," J. Immunol. Methods, 260: 157-172, 2002	—	—
	69.	ELVIN, J., Potter, C., Elliott, I., Cerundolo, V., and Townsend, A., "A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity," J. Immunol Methods, 158: 161-171, 1993	—	—
	70.	RUPPERT, J., Sidney, J., Celis, F., Kubo, R. 1, Grey, H. N., and Sette, A., "Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules," Cell, 74: 929-937, 1993	—	—
MD ↓	71.	thor STRATEN, P., Barbed, A., Seremet, I., Saeterdal, I., Zeuthen, 3., and Guldberg, P. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DCGE).," Biotechniques, 25: 244-250,1998	—	—
	72.	RAMMENSEE, H., Bachmann, J., Emmerich, N. P., Bachor, O. A., and Stevanovic, S., " SYFPEITHI: database for MHC ligands and peptide motifs," Immunogenetics, 50: 213-219, 1999	—	—

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

**Application Number**

10/715,417

**Filing Date**

**November 19, 2003**

**First Named Inventor**

Eivind Per Thor STRATEN et al.

## Art Unit

1040 1644

**Examiner Name**

Unassigned /Marianne Dibrino/

Sheet

9

of

10

**Attorney Docket Number**

**60820.000004**

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
MD	73.	SCHRAMA, D., Pedersen Ls, L. O., Keikavoussi, P., Andersen, N. H., Straten, P. P., Bocker, E. B., Kampgen, F., and Bocker, E. C., "Aggregation of antigen-specific I cells at the inoculation site of mature dendritic cells," J. Invest Dermatol., 119: 1443-1448, 2002		
	74.	MAHOTKA, C., Wenzel, N., Springer, F., Gabbert, H. E., and Gerharz, C. D., "Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties," Cancer Res., 59: 6097-6102, 1999		
	75.	HICKLIN, D. J., Marincola, F. N., and Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story," Mol. Med. Today, 5: 178-186, 1999		
	76.	SELIGER, B., Cabrera, T., Garrido, F., and Ferrone, S. HLA class I antigen abnormalities and immune escape by malignant cells," Semin. Cancer Biol., 12: 3-13, 2002		
	77.	SETTE, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. N., Melief, C. J., Oseroff, C., Yuan, F., and Ruppert, J., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," J. Immunol., 153: 5586-5592, 1994		
	78.	MOUDGIL, K. D. and Sercarz, E. E., "Can antitumor immune responses discriminate between self and nonself?," Immunol. Today, 15: 353-355, 1994		
	79.	PARKHURST, M. R., Salgaller, N. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y., "Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues," J. Immunol., 157: 2539-2548, 1996		
MD	80.	GUICHARD, C., Zerbib, A., Le Gal, F. A., Hoebeke, J., Connan, F., Choppin, J., Briand, J. P., and Guillet, J. G., "Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumor-infiltrating lymphocytes," J. Med. Chem., 43: 3803-3808, 2000		

EXAMINER SIGNATURE /Marianne Dibrino/

DATE CONSIDERED 03/12/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Application Number		10/715,417	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Filing Date		November 19, 2003	
				First Named Inventor		Eivind Per Thor STRATEN et al.	
				Art Unit		<del>1646</del> 1644	
				Examiner Name		<del>Unassigned</del> /Marianne Dibrino/	
Sheet	10	of	10	Attorney Docket Number		60820.000004	
<b>NON-PATENT LITERATURE DOCUMENTS</b>							
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION				
			YES	NO			
MD ↓	81.	CLAY, T. M., Custer, M. C., McKee, M. D., Parkhurst, N., Robbins, P. F., Kerstann, K., Wunderlich, J., Rosenberg, S. A., and Nishimura, M. I., "Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue," J. Immunol., 162: 1749-1755, 1999	—	—			
	82.	MELIEF, C. J., van der Burg, S. H., Toes, R. E., Ossendorp, F., and Offringa, R., "Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev., 188: 177-182, 2002	—	—			
	83.	JAGER, E., Ringhoffer, M., Altmannsberger, M., Arand, M., Karbach, J., Jager, D., Oesch, F., and Knuth, A., "Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma," Int. J. Cancer, 71: 142-147, 1997	—	—			
	84.	THURNER, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den, D. P., Brocker, E. B., Steinman, R. M., Enk, A., Kämpgen, E., and Schuler, G., "Vaccination with mage3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma," J. Exp. Med., 190: 1669-1678, 1999	—	—			
MD ↓	85.	YEE, C., Thompson, J. A., Roche, P., Byrd, D. P., Lee, P. P., Piepkorn, N., Kenyon, K., Davis, N. N., Riddell, S. R., and Greenberg, P. D., "Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of cell-mediated vitiligo," J. Exp. Med., 192: 1637-1644, 2000	—	—			
	86.	SIMON, R. M., Steinberg, S. M., Hamilton, M., Hildesheim, A., Khleif, S., Kwak, L. W., Mackall, C. L., Schlom, J., Topalian, S. L., and Berzofsky, J. A., "Clinical trial designs for the early clinical development of therapeutic cancer vaccines," J. Clin. Oncol., 19: 1848-1854, 2001	—	—			
EXAMINER SIGNATURE /Marianne Dibrino/				DATE CONSIDERED 03/12/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							